Blocking abnormal blood vessels to treat hepatic encephalopathy that medicine does not control
Tests closing abnormal liver blood vessels in adults with hard-to-treat hepatic encephalopathy.
Key facts
- Who runs it
- Rutgers, The State University of New Jersey
- Where
- Newark, United StatesSee the site
- Trial code
- Registry title
- Endoscopic Shunts Embolization for Refractory Hepatic Encephalopathy
- Status
- Not yet recruiting
- People taking part
- 34 people, planned
- Started
- 1 May 2026
- Expected to end
- 1 Nov 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Endoscopic ultrasound-guided transgastric embolization of the spontaneous portosystemic shunts
- Interventional Radiology for shunt embolization/retrograde tranvenous obliteration
- Record updated
- 28 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis whose hepatic encephalopathy (brain confusion caused by liver disease) keeps coming back despite medicines. They must also have a natural bypass vessel around the liver (spontaneous portosystemic shunt).
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Known cirrhosis with hepatic encephalopathy that does not respond to medicines: 2 or more episodes within 6 months before joining. People must be admitted to the inpatient hepatology floor at University Hospital-Newark at the time of joining. A spontaneous portosystemic shunt must be confirmed on CT/MRI during this admission.
- Earlier treatment
- Episodes must have happened despite treatment with lactulose and rifaximin.
Main reasons for not taking part
- Severe fluid in the belly (ascites) that does not go away with medicines or comes back quickly after draining
- Bleeding from swollen veins in the food pipe (esophageal varices) that does not stop or keeps coming back
- A blood clot fully blocking the portal vein, or liver cancer beyond Milan criteria or other advanced cancer with life expectancy under 6 months
- Platelet count less than 35,000 and/or INR more than 2 that cannot be corrected for the procedure
- Cirrhosis caused by blocked liver veins or right heart failure
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults aged ≥18 years with known cirrhosis
- MRHE; defined as ≥2 episodes of hepatic encephalopathy, HE (as documented in an outpatient office visit or during an inpatient admission) within 6 months prior to enrollment despite medical therapy with lactulose and rifaximin
- Admission to inpatient hepatology floor at University Hospital-Newark with MRHE at the time of enrollment
- Presence of a spontaneous portosystemic shunt; confirmed on CT/MRI at the index admission
Who cannot take part
- Severe/refractory ascites defined as ascites that does not recede after medical therapy or reoccurs shortly after fluid has been removed
- Refractory or recurrent bleeding from esophageal varices
- Presence of portal vein thrombosis with complete occlusion
- Hepatocellular carcinoma beyond Milan criteria or other advanced malignancy with limited life expectancy (<6 months)
- Hepatic venous occlusion, or right heart failure as the etiology of cirrhosis
- Platelet count of less than 35,000 and/or INR of more than 2 which cannot be corrected for the EUS guided embolization procedure
Where in United States
- Rutgers University HospitalNewark, United StatesContact: Kaveh Hajifathalian, MDNot yet recruiting
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if endoscopic ultrasound guided (EUS guided) spontaneous porto-systemic shunt (SPSS) embolization works to treat refractory hepatic encephalopathy in adults. It will also learn about the safety of EUS guided embolization. The main questions it aims to answer are:
Read full original descriptionShow less
1. Does EUS guided embolization maintain an acceptable safety profile? 2. Does EUS guided embolization of large SPSS result in significant clinical improvement in patients with refractory hepatic encephalopathy?
Participants will:
1. Receive EUS guided embolization or medical management. 2. Receive follow-up EUS procedures one month after embolization for assessment of the shunt patency and development of varices (embolization group). 3. Receive follow-up every week for 4 weeks to assess degree of worst episode of hepatic encephalopathy via West Haven criteria.
The 2 groups in the trial
- Interventional Radiology guided embolization/retrograde tranvenous obliteration of shuntExisting treatment, for comparison
Embolization of the porto-systemic shunt will be conducted via Trans-Jugular, Trans-Femoral, or direct Trans-hepatic access to embolize the shunt using cyanoacrylate glue, Sodium TetraDecyl Sulfate, Gelfoam, and/or vascular coil injection. The procedure will be performed under deep sedation or general anesthesia, with fluoroscopic guidance and intraprocedural antibiotic prophylaxis.
Treatment: Interventional Radiology for shunt embolization/retrograde tranvenous obliteration
- Endoscopic ultrasound guided embolization of shuntTreatment being tested
Embolization of the porto-systemic shunt will be performed via endoscopic ultrasound (EUS) transesophageal or transgastric access with a 19G fine-needle aspiration (FNA) EUS needle to embolize the shunt using cyanoacrylate glue and vascular coil injection. The procedure will be performed under general anesthesia, with fluoroscopic guidance and intraprocedural antibiotic prophylaxis.
Treatment: Endoscopic ultrasound-guided transgastric embolization of the spontaneous portosystemic shunts
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Endoscopic Ultrasound Embolization of Porto-Systemic Shunt for Management of Medically Refractory Hepatic Encephalopathy: A Randomized Trial
- Plain-language title
- Blocking abnormal blood vessels to treat hepatic encephalopathy that medicine does not controlGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 28 April 2026